# Reading list

> GLP1 Me’s appetite reading list — The GLP1 Me reading list brings together retatrutide appetite interviews, receptor experiments, tolerability trials and research on treatment interruption.

The appetite conversation begins with the interviews. The rest of this shelf follows the questions they opened.

## Interview accounts

[Perceived benefits of treatment for obesity with retatrutide](https://pubmed.ncbi.nlm.nih.gov/41216380/) is the starting point for these essays. Its subject is the experience described by phase 2 trial participants. The [appetite, eating attitudes and eating behaviours analysis](https://pubmed.ncbi.nlm.nih.gov/40916752/) belongs beside it.

I’d begin there before turning to the receptor experiments. Those human descriptions make the biology worth following.

## Trials and experiments

The [phase 2 obesity trial](https://pubmed.ncbi.nlm.nih.gov/37366315/) provides the weight and safety context. [The phase 2 diabetes trial](https://pubmed.ncbi.nlm.nih.gov/37385280/) concerns people with type 2 diabetes. The [structural receptor study](https://pubmed.ncbi.nlm.nih.gov/39019866/) and [GLP-1 receptor knockout mouse experiment](https://pubmed.ncbi.nlm.nih.gov/41997446/) address biological questions at a different scale.

Reviews about craving, mechanisms and durability provide context around the direct studies; the interruption report concerns related treatments.

## References

[1] Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial. https://doi.org/10.1016/j.obpill.2025.100220
[2] Appetite, eating attitudes, and eating behaviours during treatment with retatrutide https://pubmed.ncbi.nlm.nih.gov/40916752/
[3] Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial https://pubmed.ncbi.nlm.nih.gov/37366315/
[4] Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial https://pubmed.ncbi.nlm.nih.gov/37385280/
[5] Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide https://pmc.ncbi.nlm.nih.gov/articles/PMC11255275/
[6] GIPR:GCGR co-agonism restores normal weight in obese rodents. https://doi.org/10.1016/j.molmet.2026.102365
[7] Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes? https://doi.org/10.1111/dom.16106
[8] Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological Insights https://pmc.ncbi.nlm.nih.gov/articles/PMC12372146/
[9] Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials. https://doi.org/10.1186/s40001-026-03933-9
[10] Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption https://pmc.ncbi.nlm.nih.gov/articles/PMC12155999/
[11] Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies. https://doi.org/10.1016/j.metop.2026.100463
[12] The First Triple Agonist for Antiobesity: Retatrutide https://pubmed.ncbi.nlm.nih.gov/39724554/

---

GLP-1 Me is my table for published research on appetite, not a business or a source of medical advice.